Cargando…

Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City

BACKGROUND: Tocilizumab and baricitinib are immunomodulators that have been repurposed for the treatment of coronavirus disease 2019 (COVID-19). Whether one medication should be preferred over the other has not been established. METHODS: This multicenter retrospective cohort study comprised hospital...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sunny, Subin, Tran, Ami, Lee, Jennifer, Abdallah, Marie, Chaudhry, Nimra, Quale, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442059/ https://www.ncbi.nlm.nih.gov/pubmed/37608917 http://dx.doi.org/10.1093/ofid/ofad426

Ejemplares similares

Carbapenem-Resistant Klebsiella pneumoniae in Large Public Acute-Care Healthcare System, New York, New York, USA, 2016–2022
por: Lee, Jennifer, et al.
Publicado: (2023)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
por: Kaminski, Monica A., et al.
Publicado: (2020)

334 Emergence of OXA-23-possessing Acinetobacter baumannii in Hospitals in New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

Hepatitis C Seroprevalence Among Consecutive Labor and Delivery Admissions in Two New York City Hospitals
por: Kushner, Tatyana, et al.
Publicado: (2020)

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Carbapenem-Resistant Klebsiella pneumoniae Infection in Three New York City Hospitals Trended Downwards From 2006 to 2014
por: Park, Sun O., et al.
Publicado: (2016)

Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019
por: Tziolos, Nikolaos, et al.
Publicado: (2021)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

249 Activity of Plazomicin Against Contemporary Isolates of Enterobacteriaceae from New York City
por: Olafisoye, Olawole, et al.
Publicado: (2014)

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
por: WILLIAMS, STEPHANIE N, et al.
Publicado: (2022)

Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City
por: Sigel, Keith, et al.
Publicado: (2020)

Chagas Disease in the New York City Metropolitan Area
por: Zheng, Crystal, et al.
Publicado: (2020)

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals
por: Iregui, Alejandro, et al.
Publicado: (2019)

Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis
por: Ignatius, Elisa H, et al.
Publicado: (2020)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
por: Lakatos, Botond, et al.
Publicado: (2022)

1802 Prevalence of KPC-possessing Klebsiella pneumoniae in New York City: Have We Turned the Corner?
por: Abdallah, Marie, et al.
Publicado: (2014)

Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center
por: Sunny, Subin, et al.
Publicado: (2022)

Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2
por: Fintzi, Jonathan, et al.
Publicado: (2022)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
por: Roddy, John, et al.
Publicado: (2022)

Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001–2012
por: Moore, Miranda S, et al.
Publicado: (2018)

Candida auris Colonization After Discharge to a Community Setting: New York City, 2017–2019
por: Bergeron, Genevieve, et al.
Publicado: (2020)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Human Immunodeficiency Virus Infection Newly Diagnosed at Autopsy in New York City, 2008–2012
por: Ramaswamy, Chitra, et al.
Publicado: (2015)

Rifampin Mono-Resistant Tuberculosis in New York City, 2010–2021: A Retrospective Case Series
por: Lindsey, Joseph A, et al.
Publicado: (2023)

Hospitals, &c., of the City of New York
Publicado: (1859)

The initial and lingering impact of coronavirus disease 2019 (COVID-19) on catheter-associated infections in a large healthcare system in New York City
por: Samaroo-Campbell, Jevon, et al.
Publicado: (2022)

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial
por: Kumar, Princy N, et al.
Publicado: (2021)

Socioeconomic Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 Serological Testing and Positivity in New York City
por: Lieberman-Cribbin, Wil, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System
por: Vo, Christopher, et al.
Publicado: (2023)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

Estimated Prevalence of Tuberculosis Infection Among a New York City Clinic Population Using Interferon-gamma Release Assays
por: Stennis, Natalie L., et al.
Publicado: (2014)

Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care
por: Chan, Justin, et al.
Publicado: (2020)

Reduction in Risk of Death Among Patients Admitted With COVID-19 Between the First and Second Epidemic Waves in New York City
por: Bowen, Anthony, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1o7cp3bp1h4bqpa8q1253h6dh9